Supply Brain: Cell and Gene Therapy Supply Chain Insights

Isolation method is usually chosen once, inherited thereafter, and never revisited. It deserves more attention than that, because the two dominant approaches do not merely differ in purity. They differ in whether anythin

Mesenchymal stromal cells are among the most studied and least standardised cell products in research. The same three letters cover populations from different tissues with different behaviour, different expansion charact

LRS chambers occupy an odd position in cell sourcing. They are a by-product that turned out to be useful, they are cheap relative to what they contain, and they are almost never explained anywhere a buyer would look. The

Donor characterisation tends to stop at the point where safety is established, which leaves the most useful information unmeasured. Two donors can pass identical screening and carry immune compartments that differ enough

Immuno-oncology runs on a comparison between what immune cells do and what they could do if something were changed. Both halves of that comparison depend on the immune cells being representative of a real immune system,

Granulocyte contamination is usually discovered rather than anticipated. A phenotyping panel shows a population nobody expected, a functional assay produces a background that will not go away, or a preparation clumps dur

Most problems attributed to a flow panel are not panel problems. They are sample problems, gating problems or comparison problems that surface at the cytometer because that is where the data appears. Distinguishing betwe

Density gradient separation has been the standard way to isolate mononuclear cells for decades, and its longevity has made it invisible. Most protocols specify it without stating why, which means the alternatives rarely

Screening wants throughput, consistency and low cost per well. Primary human cells offer none of those and offer relevance instead. The productive question is not which is better but where in a campaign the switch should

Cytotoxicity assays all report killing and they do not report the same thing. One measures membrane rupture, another measures metabolic collapse, a third measures whether the effector cell released its granules at all. C

Freezing cells is treated as storage, which is the root of most of what goes wrong with it. Storage implies the cells wait, unchanged, until called upon. What actually happens is a process the cell has to survive, and th

Cord blood is frequently described as a convenient source, which undersells it. The cells in a cord blood unit are developmentally distinct from their adult counterparts in ways that change what they can do, and several

A comparability study asks whether material produced after a change behaves like material produced before it. That sounds straightforward until you notice how many things tend to change at once, and how few studies are d

CD34 is a marker of convenience that became a definition. It was identified as a surface antigen on immature haematopoietic cells, turned out to be selectable, and the population it captures has been the working definiti

B cells spent a long time as the antibody chapter in immunology courses and are now one of the more interesting targets in cell therapy. The shift came from a clinical observation rather than a theoretical one: depleting

Monocytes are the population that most often makes a PBMC preparation disappoint, and they do it quietly. They are fragile relative to lymphocytes, they respond to handling by activating, and they adhere to almost everyt

CAR-NK exists as a category because of a single biological fact: NK cells carry a markedly lower graft-versus-host risk than T cells, which makes an allogeneic off-the-shelf product plausible without engineering that ris

Most programmes assemble their donor panel by accident. Material was ordered when it was needed, donors were whoever was available, and the panel is a description of purchasing history rather than a designed resource. A

These three get used interchangeably in purchasing conversations and are not interchangeable at the bench. The difference is not simply how much you get. It is how the material was produced, what that production does to

Biomarker discovery from patient cells has a well-documented reproducibility problem, and a large share of it originates before any analysis begins. Sample handling, cohort definition and donor variables that were never

Healthy donor cells tell you how a normal immune system behaves. Autoimmune disease is a question about how an abnormal one behaves, and a substantial amount of published work answers it with healthy cells plus a stimulu

Shipping gets discussed as a logistics line item, which is how it ends up owning a variable nobody is tracking. Cells do not pause while they are in transit. Whatever happens between the collection chair and your bench i

Recurring supply is one of the more common requests in AI-assisted vendor searches and one of the least discussed on supplier websites. The underlying problem is real: a study running eighteen months does not want to pla

Pooling donors is usually presented as a way to reduce variability, which gets the statistics exactly backwards. Pooling does not reduce variability. It hides it, converts it into a fixed and unmeasurable property of you

Research use and clinical grade get discussed as if they were two labels on the same box, distinguished mainly by price. They are not. Almost everything behind the material changes, and the changes are the reason for the

The transition from research grade to clinical grade is planned as a procurement change and experienced as a scientific one. Programmes budget for a higher unit price, a longer lead time and some additional paperwork. Wh

Every cell therapy programme eventually needs more of something it already has. A comparability study after a process change, an extra arm on a dose-ranging series, a repeat of an experiment that produced an interesting

The certificate of analysis arrives with the shipment, gets glanced at, and goes into a folder. It is the densest piece of information you will receive about material you are about to build months of work on, and most of

Two labs process the same leukopak format from the same supplier and report yields that differ by a wide margin. Neither did anything wrong in the sense of breaking protocol. The variance comes from a handful of decision

An NK cytotoxicity assay across four donors produces four different curves. The vials matched on CD56 purity and post-thaw viability, the operator was the same, the target line was the same. The usual conclusion is that

Request quotes from five PBMC suppliers and you will get five documents that look almost identical. Viability above ninety percent, healthy donors, IRB-approved consent, research grade, cryopreserved. The specifications

The word matched does a great deal of unexamined work in this market. It appears on quotes, in capability decks and in conversations, and it very rarely comes with the one qualifier that determines whether it means anyth

Donor screening gets treated as a box that either is or is not ticked, which is roughly as useful as describing a car as having an engine. Screening answers a narrow and important question about safety. It does not answe

Most catalogues describe a fraction of what a cell processing operation can actually do, which is why the useful question is rarely whether something is on the list. It is whether the population you want can be isolated

Search for a cell therapy manufacturing partner and you will find rankings. Top ten lists, market landscape reports, capability matrices where every provider ticks every box. They are useful for discovering that a compan

Ask three suppliers to quote the same nominal product and the numbers can differ by an order of magnitude. That spread is not evidence that someone is overcharging. It usually means the three quotes describe materially d

Biospecimen sourcing looks like procurement and behaves like experimental design. The material you buy carries a donor, a collection history and a set of decisions that were made before you were involved, and all three a

Crohn’s disease sits at an awkward junction for anyone using peripheral blood. The pathology is transmural, focal and located in the gut, the driving interaction involves the intestinal microbiota, and the cells you can

Type 1 diabetes presents research with an awkward arithmetic problem. The cells that matter most are the ones targeting islet antigens, and they are vanishingly rare in circulation. Detecting them reliably is a technical

Ulcerative colitis gets studied alongside Crohn’s disease more often than the biology justifies. The convenience is real, since recruitment is easier and cohorts are larger, but the two conditions differ in distribution,